Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOSGet Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Monday, MarketBeat.com reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 312.37% from the company’s current price. HC Wainwright also issued estimates for Atossa Therapeutics’ Q4 2023 earnings at ($0.05) EPS, FY2023 earnings at ($0.23) EPS, Q1 2024 earnings at ($0.06) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.26) EPS, FY2025 earnings at ($0.37) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.36) EPS.

Other equities research analysts have also issued reports about the company. StockNews.com upgraded Atossa Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research note on Friday, January 12th.

Read Our Latest Stock Analysis on ATOS

Atossa Therapeutics Stock Performance

Shares of NASDAQ:ATOS opened at $0.97 on Monday. Atossa Therapeutics has a 52-week low of $0.59 and a 52-week high of $1.39. The stock’s fifty day simple moving average is $0.84 and its 200-day simple moving average is $0.81.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last released its earnings results on Monday, November 13th. The company reported ($0.05) earnings per share for the quarter. On average, equities research analysts anticipate that Atossa Therapeutics will post -0.2 EPS for the current fiscal year.

Institutional Trading of Atossa Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp grew its holdings in shares of Atossa Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 227,922 shares of the company’s stock worth $201,000 after acquiring an additional 13,280 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of Atossa Therapeutics by 14.8% in the 3rd quarter. GSA Capital Partners LLP now owns 347,392 shares of the company’s stock worth $256,000 after acquiring an additional 44,788 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Atossa Therapeutics in the 3rd quarter worth $98,000. UBS Group AG acquired a new position in shares of Atossa Therapeutics in the 3rd quarter worth $25,000. Finally, XTX Topco Ltd acquired a new position in shares of Atossa Therapeutics in the 2nd quarter worth $50,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Articles

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.